1
|
Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, Habrand JL, Saintigny Y, Joly F. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget 2017; 8:69105-69124. [PMID: 28978184 PMCID: PMC5620324 DOI: 10.18632/oncotarget.19079] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2017] [Accepted: 06/19/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Poly-(ADP-Ribose)-Polymerase (PARP) inhibitors are becoming important actors of anti-neoplasic agents landscape, with recent but narrow FDA's approvals for ovarian BRCA mutated cancers and prostatic cancer. Nevertheless, PARP inhibitors are also promising drugs for combined treatments particularly with radiotherapy. More than seven PARP inhibitors have been currently developed. Central Role of PARP in DNA repair, makes consider PARP inhibitor as potential radiosensitizers, especially for tumors with DNA repair defects, such as BRCA mutation, because of synthetic lethality. Furthermore the replication-dependent activity of PARP inhibitor helps to maintain the differential effect between tumoral and healthy tissues. Inhibition of chromatin remodeling, G2/M arrest, vasodilatory effect induced by PARP inhibitor, also participate to their radio-sensitization effect. MATERIALS AND METHODS Here, after highlighting mechanisms of PARP inhibitors radiosensitization we methodically searched PubMed, Google Scholar, Cochrane Databases and meeting proceedings for human pre-clinical and clinical studies that evaluated PARP inhibitor radiosensitizing effect. Enhancement ratio, when available, was systematically reported. RESULTS Sixty four studies finally met our selection criteria and were included in the analysis. Only three pre-clinical studies didn't find any radiosensitizing effect. Median enhancement ratio vary from 1,3 for prostate tumors to 1,5 for lung cancers. Nine phase I or II trials assessed safety data. CONCLUSION PARP inhibitors are promising radiosensitizers, but need more clinical investigation. The next ten years will be determining for judging their real potential.
Collapse
Affiliation(s)
- Paul Lesueur
- Laboratoire d'Accueil et de Recherche avec les Ions Accélérés, CEA, CIMAP-GANIL, 14000 Caen, France.,Centre Francois Baclesse Centre de Lutte Contre le Cancer, Radiotherapy Unit, 14000 Caen, France
| | - François Chevalier
- Laboratoire d'Accueil et de Recherche avec les Ions Accélérés, CEA, CIMAP-GANIL, 14000 Caen, France
| | - Jean-Baptiste Austry
- Laboratoire d'Accueil et de Recherche avec les Ions Accélérés, CEA, CIMAP-GANIL, 14000 Caen, France
| | - Waisse Waissi
- EA 3430, Laboratoire de Radiobiologie, Centre Paul Strauss, 67000 Strasbourg, France
| | - Hélène Burckel
- EA 3430, Laboratoire de Radiobiologie, Centre Paul Strauss, 67000 Strasbourg, France
| | - Georges Noël
- EA 3430, Laboratoire de Radiobiologie, Centre Paul Strauss, 67000 Strasbourg, France
| | - Jean-Louis Habrand
- Centre Francois Baclesse Centre de Lutte Contre le Cancer, Radiotherapy Unit, 14000 Caen, France
| | - Yannick Saintigny
- Laboratoire d'Accueil et de Recherche avec les Ions Accélérés, CEA, CIMAP-GANIL, 14000 Caen, France
| | - Florence Joly
- Centre Francois Baclesse Centre de Lutte Contre le Cancer, Clinical Research Unit, 14000 Caen, France
| |
Collapse
|
2
|
Guy JB, Rancoule C, Méry B, Espenel S, Wozny AS, Simonet S, Vallard A, Alphonse G, Ardail D, Rodriguez-Lafrasse C, Magné N. [Radiosensitivity and/or radioresistance of head and neck cancers: Biological angle]. Bull Cancer 2015; 103:41-7. [PMID: 26702507 DOI: 10.1016/j.bulcan.2015.10.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2015] [Revised: 10/28/2015] [Accepted: 10/30/2015] [Indexed: 01/01/2023]
Abstract
Radiation therapy is a cornerstone of head and neck cancer management. Technological improvements in recent years in radiation therapy, with intensity-modulated techniques, reinforce even more its role. However, both local and locoregional relapses are still observed. Understanding biological mechanisms of treatment resistance is a topic of major interest. From the cancer cell itself, its ability to repair and proliferate, its microenvironment and oxygenation conditions, migratory and invasive capacity, to biological parameters related to the patient, there are many mechanisms involving radiosensitivity and/or radioresistance of head and neck cancer. The present study explores the main biological mechanisms involved in radiation resistance of head and neck cancer, and describes promising therapeutic approaches.
Collapse
Affiliation(s)
- Jean-Baptiste Guy
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France; Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Chloé Rancoule
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France
| | - Benoîte Méry
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France; Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Sophie Espenel
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France
| | - Anne-Sophie Wozny
- Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Stéphanie Simonet
- Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Alexis Vallard
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France
| | - Gersende Alphonse
- Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Dominique Ardail
- Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Claire Rodriguez-Lafrasse
- Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France
| | - Nicolas Magné
- Institut de cancérologie de la Loire-Lucien-Neuwirth, département de radiothérapie, 108, bis, avenue Albert-Raimond, BP 60008, 42271 Saint-Priest-en-Jarez, France; Faculté de médecine Lyon-Sud, laboratoire de radiobiologie cellulaire et moléculaire de Lyon-Sud, EMR 3738, 165, chemin du Grand-Revoyet, BP 12, 69921 Oullins cedex, France.
| |
Collapse
|
3
|
Burckel H, Josset E, Denis JM, Gueulette J, Slabbert J, Noël G, Bischoff P. Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture. Oncol Rep 2014; 33:471-7. [PMID: 25371289 DOI: 10.3892/or.2014.3590] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Accepted: 10/02/2014] [Indexed: 11/06/2022] Open
Abstract
The present in vitro study aimed to assess the effects of combining the mTOR inhibitor RAD001 and temozolomide (TMZ) together with irradiation by either low-linear energy transfer (LET) radiation (γ-rays) or high-LET radiation (fast neutrons) on the growth and cell survival of the human glioblastoma cell line U-87. We observed a strong decrease in cell proliferation along with a concomitant increase in cell death as a function of the radiation dose. As expected, high-LET radiation was more effective and induced more sustained damage to DNA than low-LET radiation. While RAD001 in association with TMZ induced autophagic cell death, additional combination with either type of radiation did not further increase its occurrence. On the contrary, apoptosis remained at a low level in all experimental groups.
Collapse
Affiliation(s)
- Hélène Burckel
- EA 3430, University of Strasbourg, Centre Paul Strauss, Strasbourg, France
| | - Elodie Josset
- EA 3430, University of Strasbourg, Centre Paul Strauss, Strasbourg, France
| | | | | | | | - Georges Noël
- EA 3430, University of Strasbourg, Centre Paul Strauss, Strasbourg, France
| | - Pierre Bischoff
- EA 3430, University of Strasbourg, Centre Paul Strauss, Strasbourg, France
| |
Collapse
|
4
|
Habrand JL, Datchary J, Alapetite C, Bolle S, Calugaru V, Feuvret L, Helfre S, Stefan D, Delacroix S, Demarzi L, Dendale R. Évolution des indications cliniques en hadronthérapie 2008–2012. Cancer Radiother 2013; 17:400-6. [DOI: 10.1016/j.canrad.2013.07.141] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2013] [Accepted: 07/16/2013] [Indexed: 12/25/2022]
|
5
|
Genet SC, Maeda J, Fujisawa H, Yurkon CR, Fujii Y, Romero AM, Genik PC, Fujimori A, Kitamura H, Kato TA. Comparison of cellular lethality in DNA repair-proficient or -deficient cell lines resulting from exposure to 70 MeV/n protons or 290 MeV/n carbon ions. Oncol Rep 2012; 28:1591-6. [PMID: 22923057 DOI: 10.3892/or.2012.1982] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2012] [Accepted: 06/26/2012] [Indexed: 11/06/2022] Open
Abstract
Charged particle therapy utilizing protons or carbon ions has been rapidly intensifying over recent years. The present study was designed to jointly investigate these two charged particle treatment modalities with respect to modeled anatomical depth-dependent dose and linear energy transfer (LET) deliveries to cells with either normal or compromised DNA repair phenotypes. We compared cellular lethality in response to dose, LET and Bragg peak location for accelerated protons and carbon ions at 70 and 290 MeV/n, respectively. A novel experimental live cell irradiation OptiCell™ in vitro culture system using three different Chinese hamster ovary (CHO) cells as a mammalian model was conducted. A wild-type DNA repair-competent CHO cell line (CHO 10B2) was compared to two other CHO cell lines (51D1 and xrs5), each genetically deficient with respect to one of the two major DNA repair pathways (homologous recombination and non-homologous end joining pathways, respectively) following genotoxic insults. We found that wild-type and homologous recombination-deficient (Rad51D) cellular lethality was dependent on both the dose and LET of the carbon ions, whereas it was only dependent on dose for protons. The non-homologous end joining deficient cell line (Ku80 mutant) showed nearly identical dose-response profiles for both carbon ions and protons. Our results show that the increasingly used modality of carbon ions as charged particle therapy is advantageous to protons in a radiotherapeutic context, primarily for tumor cells proficient in non-homologous end joining DNA repair where cellular lethality is dependent not only on the dose as in the case of more common photon therapeutic modalities, but more importantly on the carbon ion LETs. Genetic characterization of patient tumors would be key to individualize and optimize the selection of radiation modality, clinical outcome and treatment cost.
Collapse
Affiliation(s)
- Stefan C Genet
- Department of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|